• clinical
  • This disorder is differentiated from all other forms of HL, which are commonly referred to as classical Hodgkin lymphomas (cHLs), by characteristic pathologic and clinical features. (uptodate.com)
  • See 'Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma' . (uptodate.com)
  • After reassessment of histological samples for the presence of MALT lymphoma, patients were evaluated as regards date of diagnosis, prior therapy for MALT lymphoma, sites of involvement upon treatment with rituximab, clinical response in terms of complete remission (CR), partial response ( PR), stable disease (SD) and progressive disease as well as symptomatic response, duration of response and survival. (icr.ac.uk)
  • CD20
  • Prior CD20 immunophenotyping of tumors to document B cell NHL is acceptable. (clinicaltrials.gov)
  • Owing to its B cell lineage, it appears to be a potential target for treatment with the CD20 antibody rituximab. (icr.ac.uk)
  • In 1 patient with SD, however, persistence of CD20-positive cells within lymphoepithelial lesions was noted in spite of almost complete depletion of B lymphocytes from the normal gastric mucosa, suggesting either recirculation of MALT lymphoma cells to these lesions or defining lymphoepithelial lesions as a sanctuary site from rituximab penetration. (icr.ac.uk)